Disease · MONDO_0024609

vulvar squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. vulvar squamous cell carcinoma. Diseases, record MONDO_0024609. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024609

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: vulvar squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0024609; Open Targets
Other names: epidermoid carcinoma of the vulva, epidermoid carcinoma of vulva, epidermoid cell carcinoma of the vulva, epidermoid cell carcinoma of vulva, mammalian vulva squamous cell carcinoma, squamous cell carcinoma of the vulva, squamous cell carcinoma of vulva, vulva epidermoid carcinoma, vulva epidermoid cell carcinoma, vulva squamous cell carcinoma, vulvar epidermoid carcinoma, vulvar epidermoid cell carcinoma, vulvar squamous cell cancer; Open Targets
Disease Ontology: DOID:2101; Disease Ontology
NCI Thesaurus: C4052; NCI Thesaurus
Orphanet: ORPHA:494448; Orphanet
Highest stage of its drugs: Phase 2, for 9 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	2	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/29126	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
HDAC1	Histone deacetylase 1	1	Histone deacetylase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase 2	1	Histone deacetylase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase 3	1	Histone deacetylase 3 inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Protein deacetylase HDAC6	1	Histone deacetylase 6 inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00068406	Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva	Phase 2	61	2017-10-17	Stage III Vulvar Cancer, Stage IVB Vulvar Cancer, Vulvar Squamous Cell Carcinoma	CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01595061	Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva	Phase 2	57	2021-12-29	Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IVA Vulvar Cancer AJCC v7, Vulvar Squamous Cell Carcinoma	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00476476	Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar	Phase 2	41	2015-03-19	Squamous Cell Carcinoma	ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT04969887	Combination Immunotherapy in Rare Cancers Under InvesTigation	Phase 2	240		Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT04357873	Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations	Phase 2	112		Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer	PEMBROLIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03212469	A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer	Phase 1/2	54		Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT05903833	Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy	Phase 2	42		Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT07101848	A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER	Phase 2	42		Vulvar Cancers	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT05761132	Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study	Phase 2	40		Vulva Cancer, Vulva Neoplasm, Squamous Cell Cancer	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04430699	Cisplatin+Pembrolizumab+RT in Vulvar Cancer	Phase 2	24		Vulvar Cancer, Vulvar Squamous Cell Carcinoma	CISPLATIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22750258	RESULT	1	PubMed
41468684	DERIVED	1	PubMed
41231502	DERIVED	1	PubMed
40608313	DERIVED	1	PubMed
40588522	DERIVED	1	PubMed
38909994	DERIVED	1	PubMed
38574312	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024609

GET https://conductscience.org/api/diseases/v1/MONDO_0024609/targets?page=2

API reference For AI assistants